Rochester Medical Corporation Stock Upgraded (ROCM)
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK (TheStreet) -- Rochester Medical Corporation (Nasdaq:ROCM) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- The revenue growth came in higher than the industry average of 7.6%. Since the same quarter one year prior, revenues rose by 24.6%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- ROCM has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 6.16, which clearly demonstrates the ability to cover short-term cash needs.
- ROCHESTER MEDICAL CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, ROCHESTER MEDICAL CORP turned its bottom line around by earning $0.16 versus -$0.10 in the prior year. This year, the market expects an improvement in earnings ($0.52 versus $0.16).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 1449.3% when compared to the same quarter one year prior, rising from -$0.08 million to $1.01 million.
- Powered by its strong earnings growth of 900.00% and other important driving factors, this stock has surged by 56.77% over the past year, outperforming the rise in the S&P 500 Index during the same period. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
-- Written by a member of TheStreet Ratings Staff
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
Latest Headlines about ROCM
-
Rochester Medical Corporation's CEO Discusses Q3 2012 Results - Earnings Call Transcript
04:33PM 07/27/12
-
Rochester Medical Corporation's CEO Discusses Q2 2012 Results - Earnings Call Transcript
06:54PM 04/24/12
-
Rochester Medical CEO Discusses F1Q2012 Results - Earnings Call Transcript
06:38PM 01/25/12
-
Rochester Medical's CEO Discusses F4Q 2011 Results - Earnings Call Transcript
06:59PM 11/03/11
-
Rochester Medical Discusses Q2 2011 Results -- Earnings Call Transcript
04:59PM 07/29/11
-
TheStreet Ratings Upgrades & Downgrades
01:33PM 05/31/11
-
Rochester Medical's CEO Discusses F2Q11 Results - Earning Call Transcript
09:18PM 05/05/11
Latest from TheStreet Wire
-
Axis Capital Holdings Ltd (AXS): Today's Featured Insurance Laggard
05:01PM 05/17/13
-
Validus Holdings Inc. (VR): Today's Featured Financial Laggard
05:01PM 05/17/13
-
Cavium Inc (CAVM): Today's Featured Electronics Laggard
05:01PM 05/17/13
-
Smithfield Foods Inc. (SFD): Today's Featured Consumer Goods Laggard
05:01PM 05/17/13
-
Autodesk Inc. (ADSK): Today's Featured Computer Software & Services Laggard
05:01PM 05/17/13
-
Goldcorp Inc. (GG): Today's Featured Basic Materials Laggard
05:01PM 05/17/13
-
Finisar Corporation (FNSR): Today's Featured Technology Laggard
05:01PM 05/17/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
